Hadassah

Life After Childhood Cancer: Hadassah Assesses Kids’ Self-Esteem

Wednesday, Dec 23 2015

An illustration of a healthy eye versus an eye with retinoblastoma.

“The cure cannot be limited to freedom from cancer, but must also afford childhood cancer survivors the same physical and psychological quality of life enjoyed by their healthy peers,” says Prof. Michael Weintraub, Director of the Hadassah Medical Center’s Department of Pediatric Hemato-Oncology.

Over 95 percent of children are cured of a malignant eye tumor called retinoblastoma (RB). But what quality of life do survivors of this childhood cancer have? This is a question that Hadassah is researching with the ultimate goal of designing an intervention program that will address the  deficits these children experience.

As Prof. Weintraub explains: The side effects of the various treatments may have psychological and social consequences-- impaired self-esteem and body image, as well as lower academic achievements. Hadassah is devoted to delineating those areas in which the quality of life for these cancer survivors has been compromised, either by the disease or treatment.

RB is a malignant eye tumor that occurs exclusively in infants and children. In some children, only one eye is affected; in others, both eyes have RB. Approximately 40% of the cases are hereditary. Typically, children are diagnosed within the first two years of life. A mother may, for example, be alerted that her toddler has a problem when he begins crawling into objects, rather than around them.

Long-term survivors of retinoblastoma who have received radiation therapy at an early age develop a typical deformity of their facial bones and soft tissues (midfacial hypoplasia). There is also loss of vision, due either to loss of one eye or varying degrees of decrease in visual acuity, caused by the tumor or treatment.

In the initial phase of a research study carried out in collaboration with Dr. Naomi Weintraub from the School of Occupational Therapy and Prof. Jacob Pe'er, Chairman of the Department of Ophthalmology, the team conducted a comprehensive assessment of the quality of life in a group of children cured of retinoblastoma. After investigating their physical, emotional, social, and academic well-being, they found that these children had lower self-esteem and poorer emotional health as judged by their parents, as well as a lower quality of life at school.

The second phase of the study is currently assessing body image and vision-related deficits in motor function and coordination. Since patients with retinoblastoma often undergo removal of the affected eye, even though the child is cured of the cancer, the impact appears to be significant on the young patients' self-perception, with social and interpersonal adverse consequences. At the same time, the cancer survivors may experience vision-related impairments in motor function and coordination since removal of the eye puts them at risk for impairments in this domain.

Once all the data is analyzed, Hadassah will design the comprehensive intervention program that will address these deficits in quality of life, body image, and vision-related motor function and coordination.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Aug 16 2017

Gazan Boy Walks for First Time at Hadassah

Unable to stand on his feet, suffering from severe respiratory distress, a four-year-old boy from Gaza gained the ability to walk once Hadassah Hospital surgeons identified and removed a large tumor lodged in his chest.

READ MORE ›
alt_text

Wednesday, Aug 16 2017

Hadassah Hosts Health Innovation Conference

Over one hundred doctors, researchers, and entrepreneurs gathered at Hadassah Hospital Ein Kerem this summer to discuss how to advance the quality of patient care with computational power.

READ MORE ›
alt_text

Monday, Aug 14 2017

Hadassah Hosts First Human Trial with Drug to Fight Nasty Bacterial Infection

Immuron, an Australian biopharmaceutical company, has received approval from the Hadassah Medical Organization’s ethics committee and Israel’s Ministry of Health to begin its first clinical trial with a new drug to fight a bacterial infection called Clostridium Difficile (CDI).

READ MORE ›
alt_text

Thursday, Aug 3 2017

Mystery of Devastating Pediatric Disease Solved by Hadassah Team

A genetic mutation causing a rare and devastating pediatric neurological disease that has puzzled medical centers around the world has been identified at the Hadassah Medical Organization by Prof. Orly Elpeleg, head of Hadassah's Department of Genetics and Metabolic Diseases.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More